{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05938725",
            "orgStudyIdInfo": {
                "id": "KYSA-1"
            },
            "secondaryIdInfos": [
                {
                    "id": "KYV101-001",
                    "type": "OTHER",
                    "domain": "Kyverna Therapeutics"
                }
            ],
            "organization": {
                "fullName": "Kyverna Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "KYSA-1: Study on Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis",
            "officialTitle": "KYSA-1: A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Kidney Involvement in Lupus",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "kysa-study-on-anti-chimeric-antigen-receptor-t-cell-car-t-therapy-in-subjects-with-refractory-lupus-nephritis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-10-11",
            "studyFirstSubmitQcDate": "2023-07-07",
            "studyFirstPostDateStruct": {
                "date": "2023-07-10",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Kyverna Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Refractory Lupus Nephritis",
            "detailedDescription": "Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of organ involvement and disease severity. Renal involvement (categorized as lupus nephritis \\[LN\\]) may occur in approximately 50% of SLE patients and is marked by proteinuria, microscopic hematuria, and varying degrees of renal insufficiency. B cells play a central role in the pathogenesis of SLE and LN, with autoantibodies developing as an early finding, and local, tissue resident B cells producing pathogenic autoantibodies and driving inflammation and tissue damage over time. CD19-targeted chimeric antigen receptor (CAR) T cells harness the ability of cytotoxic T cells to directly and specifically lyse target cells to effectively deplete B cells in the circulation and in lymphoid and potentially non-lymphoid tissues. KYV-101, a fully human anti-CD19 CAR T-cell therapy, will be investigated in adult subjects with refractory lupus nephritis."
        },
        "conditionsModule": {
            "conditions": [
                "Lupus Nephritis",
                "Lupus Nephritis - World Health Organization (WHO) Class III",
                "Lupus Nephritis - WHO Class IV"
            ],
            "keywords": [
                "KYV-101",
                "glomerulonephritis",
                "autoimmune disease",
                "anti-CD19 CAR-T therapy",
                "cellular therapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 1)",
                    "type": "EXPERIMENTAL",
                    "description": "Dosing with KYV-101 CAR T cells",
                    "interventionNames": [
                        "Biological: KYV-101 anti-CD19 CAR-T cell therapy",
                        "Drug: Standard lymphodepletion regimen"
                    ]
                },
                {
                    "label": "KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 2)",
                    "type": "EXPERIMENTAL",
                    "description": "Recommended Phase 2 Dose",
                    "interventionNames": [
                        "Biological: KYV-101 anti-CD19 CAR-T cell therapy",
                        "Drug: Standard lymphodepletion regimen"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "KYV-101 anti-CD19 CAR-T cell therapy",
                    "description": "KYV-101 anti-CD19 CAR-T cell therapy",
                    "armGroupLabels": [
                        "KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 1)",
                        "KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 2)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Standard lymphodepletion regimen",
                    "description": "Standard lymphodepletion regimen",
                    "armGroupLabels": [
                        "KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 1)",
                        "KYV-101 CAR-T cells with lymphodepletion conditioning (Phase 2)"
                    ],
                    "otherNames": [
                        "Cyclophosphamide",
                        "Fludarabine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence adverse events (AEs) and laboratory abnormalities (Phase 1 and Phase 2)",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "Frequency of dose limiting toxicities at each dose level (Phase 1)",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To Evaluate efficacy (Phase 2)",
                    "description": "Complete renal response rates (CRR)",
                    "timeFrame": "Up to 52 Weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To characterize the pharmacokinetics (PK) (Phase 1 and Phase 2)",
                    "description": "Levels of KYV-101 CAR-positive T cells in the blood",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To characterize the pharmacodynamics (PD) (Phase 1 and Phase 2)",
                    "description": "Levels of B cells in the blood",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To characterize the pharmacodynamics (PD) (Phase 1 and Phase 2)",
                    "description": "Levels of cytokines in serum",
                    "timeFrame": "Up to 2 months"
                },
                {
                    "measure": "To evaluate disease related biomarkers (Phase 1 and Phase 2)",
                    "description": "Levels of anti-double stranded DNA (anti-dsDNA) in serum",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To evaluate disease related biomarkers (Phase 1 and Phase 2)",
                    "description": "Levels of complement C3, C4 in serum",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To evaluate efficacy (Phase 1 and Phase 2)",
                    "description": "Complete renal response rates (CRR)",
                    "timeFrame": "12, 24, and 52 weeks"
                },
                {
                    "measure": "To evaluate efficacy (Phase 1 and Phase 2)",
                    "description": "Time to Complete renal response rates (CRR)",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To evaluate efficacy (Phase 1 and Phase 2)",
                    "description": "Time from first achieved CRR to disease worsening or end of study",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To evaluate efficacy (Phase 2)",
                    "description": "Duration of CRR to Week 52 but no less than 12 weeks (duration of remission)",
                    "timeFrame": "Up to 52 weeks"
                },
                {
                    "measure": "To evaluate the immunogenicity (humoral response) of KYV-101 (Phase 1 and Phase 2)",
                    "description": "Percentage of participants who develop anti-KYV-101 antibodies by immunoassays",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To assess PRO after infusion of KYV-101 (Phase 1 and Phase 2)",
                    "description": "Change from Baseline in SF-36",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To assess PRO after infusion of KYV-101 (Phase 1 and Phase 2)",
                    "description": "Change from Baseline in FACIT-F",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To assess PRO after infusion of KYV-101 (Phase 1 and Phase 2)",
                    "description": "Change from Baseline in Lupus QoL Questionnaire",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To assess PRO after infusion of KYV-101 (Phase 1 and Phase 2)",
                    "description": "Change from Baseline in WPAI",
                    "timeFrame": "Up to 2 years"
                },
                {
                    "measure": "To define the Recommended Phase 2 Dose (RP2D) (Phase 1)",
                    "timeFrame": "Up to 2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \u226518 years\n2. Clinical diagnosis of SLE according to 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria\n3. Biopsy-proven proliferative LN Class III or IV according to 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) criteria\n4. Positive anti-nuclear antibody (ANA) (titer \u22651:80 ), anti-dsDNA (\u226530 IU/mL on enzyme-linked immunosorbent assay \\[ELISA\\]), or anti-Smith at screening or by documented medical history\n5. Up to date on recommended vaccinations, including against coronavirus disease 2019 (COVID-19)/ severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), per Centers for Disease Control and Prevention (CDC) or institutional guidelines for immune compromised individuals\n\nExclusion Criteria:\n\n1. Rapidly progressive glomerulonephritis; history of or currently active severe central nervous system (CNS) lupus, including cerebritis, cerebrovascular accident, and seizures\n2. Prior treatment with cellular immunotherapy (CAR-T) or gene therapy product directed at any target\n3. History of allogeneic or autologous stem cell transplant\n4. Evidence of active hepatitis B or hepatitis C infection\n5. Positive serology for HIV\n6. Primary immunodeficiency\n7. History of splenectomy\n8. History of stroke, seizure, dementia, Parkinson's disease, coordination movement disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic disorder investigator considers would increase the risk for the subject\n9. Impaired cardiac function or clinically significant cardiac disease\n10. Previous or concurrent malignancy with the following exceptions:\n\n    1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to screening)\n    2. In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to screening\n    3. A primary malignancy which has been completely resected, or treated, and is in complete remission for at least 5 years prior to screening",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Kyverna Therapeutics",
                    "role": "CONTACT",
                    "phone": "510-925-2484",
                    "email": "Clinicaltrials@kyvernatx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "MD",
                    "affiliation": "Kyverna Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford University Medical Center",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                },
                {
                    "facility": "University of Colorado",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "University of Massachusetts Worcester",
                    "status": "RECRUITING",
                    "city": "Worcester",
                    "state": "Massachusetts",
                    "zip": "01655",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.26259,
                        "lon": -71.80229
                    }
                },
                {
                    "facility": "Northwell Health",
                    "status": "RECRUITING",
                    "city": "Great Neck",
                    "state": "New York",
                    "zip": "11021",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.80066,
                        "lon": -73.72846
                    }
                },
                {
                    "facility": "Ohio State University Wexner Medical Center",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Ohio",
                    "zip": "43210",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.96118,
                        "lon": -82.99879
                    }
                },
                {
                    "facility": "University of Pennsylvania",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "31959992",
                    "type": "BACKGROUND",
                    "citation": "Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20. Erratum In: Nat Med. 2020 May;26(5):803. doi: 10.1038/s41591-020-0864-x."
                },
                {
                    "pmid": "36109639",
                    "type": "BACKGROUND",
                    "citation": "Mackensen A, Muller F, Mougiakakos D, Boltz S, Wilhelm A, Aigner M, Volkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rosler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Kronke G, Schett G. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15. Erratum In: Nat Med. 2023 Nov;29(11):2956. doi: 10.1038/s41591-022-02091-9."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009393",
                    "term": "Nephritis"
                },
                {
                    "id": "D000008181",
                    "term": "Lupus Nephritis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000005921",
                    "term": "Glomerulonephritis"
                },
                {
                    "id": "D000008180",
                    "term": "Lupus Erythematosus, Systemic"
                },
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9031",
                    "name": "Glomerulonephritis",
                    "relevance": "LOW"
                },
                {
                    "id": "M12338",
                    "name": "Nephritis",
                    "asFound": "Nephritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11178",
                    "name": "Lupus Nephritis",
                    "asFound": "Lupus Nephritis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11177",
                    "name": "Lupus Erythematosus, Systemic",
                    "relevance": "LOW"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T2525",
                    "name": "Glomerulonephritis",
                    "relevance": "LOW"
                },
                {
                    "id": "T3523",
                    "name": "Lupus Nephritis",
                    "asFound": "Lupus Nephritis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}